Apoptotic and chemotherapeutic properties of iron(III)-salophene in an ovarian cancer animal model

Drug Design, Development and Therapy

Volumn , Issue 3, 2009, Pages 17-26

  Lange, Thilo S ^a,b   McCourt, Carolyn ^b   Singh, Rakesh K ^b   Kyu, Kwang Kim ^b   Singh, Ajay P ^c   Luisi, Brian S ^d   Alptürk, Onur ^e   Strongin, Robert M ^f   Brard, Laurent ^b,g,h  

^a BROWN UNIVERSITY   (United States)

^b WOMEN AND INFANTS HOSPITAL   (United States)

^c RUTGERS UNIVERSITY   (United States)

^d BROWN UNIVERSITY   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f PORTLAND STATE UNIVERSITY   (United States)

^g BROWN UNIVERSITY   (United States)

^h Division of Gynecologic Oncology   (United States)

Author keywords

Chemotherapeutic properties; Iron(III) salophene; Ovarian cancer animal model; p38 MAPK

Indexed keywords

FERRIC FERROCYANIDE; IRON(III) SALOPHENE; ORGANOMETALLIC COMPOUND; PLATINUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; LD 50; MITOCHONDRIAL MEMBRANE; NONHUMAN; OVARY CANCER; RAT;

EID: 77949886671     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Heintz APM, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT. International Federation of Gynecology and Obstetrics 25th Annual Report. Carcinoma of the Ovary. Int J Gyn Obst. 2003;83:135-137.
2. American Cancer Society. Cancer facts and figures. 2007. Cited on Nov 6, 2008. Available from http://www.cancer.org.
3. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1-6. (Pubitemid 26012496)
4. McGuire WP, Ozols RF. Chemotherapy of advanced ovarian cancer. Semin Oncol. 1998;25:340-348.
5. Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst. 2000;92:699-708. (Pubitemid 30365530)
6. Leitao MM Jr, Hummer A, Dizon DS, et al. Platinum re-treatment of platinum-resistant ovarian cancer after non-platinum therapy. Gynecol Oncol. 2003;91:123-129. (Pubitemid 37188601)
7. Lamberth E, Gregory WM, Nelstrop AE, Rustin GJ. Long-term survival in 463 women treated with platinum analogs for advanced epithelial carcinoma of the ovary: life expectancy compared to women of an age-matched normal population. Int J Gynecol Cancer. 2004;14:772-778.
8. Ott I, Gust R. Non platinum metal complexes as anti-cancer drugs. Arch Pharm. 2007;340:117-126. (Pubitemid 46953741)
9. Andrews P, Howell S. Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cell. 1990;2:35-43. (Pubitemid 20218552)
10. Horowitz N, Hua J, Gibb R, Mutch D, Herzog T. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model. Gynecol Oncol. 2004;94:67-73. (Pubitemid 38950500)
11. Köpf-Maier P. Complexes of metals other than platinum as antitumour agents. Eur J Clin Pharmacol. 1994;47:1-16. (Pubitemid 24281305)
12. Huang R, Wallquist A, Covell DG. Anticancer metal compounds in NCI-s tumor-screening database: putative mode of action. Biochem Pharmacol. 2005;69:1009-1039. (Pubitemid 40349015)
13. Zhong X, Weih, Liu WS, Wang DQ, Wang X. The crystal structures of copper(II), manganese(II), and nickel(II) complexes of a (Z)-2-hydroxy-N′- (2-oxoindolin-3-ylidene) benzohydrazide-potential antitumor agents. Bioorg Med Chem Lett. 2007;17:3774-3777. (Pubitemid 46898793)
14. Lange TS, Kim KK, Singh RK, Strongin RM, McCourt CK, Brard L. Iron(III)-salophene: An metallo-organic compound with selective cytotoxic and anti-proliferative properties in platinum-resistant ovarian cancer cells. PLOS One. 2008;3(e2303):1-10.
15. Bi C, Fan Y, Sun G, Zheng G, Zhang G. Synthesis and characterization of Ln(III) complexes with N,N′-p-phenylenebis-(o-vanillylideneimine). Syn React Inorg Met. 2001;31:219-225. (Pubitemid 33589741)
16. Rose GS, Tocco LM, Granger GA, et al. Development and characterization of a clinically useful animal model of epithelial ovarian cancer in the Fischer 344 rat. Am J Obstet Gynecol. 1996;175:593-599. (Pubitemid 126689814)
17. Lange TS, Singh RK, Kim KK, et al. Anti-proliferative and pro-apoptotic Properties of 3-Bromoacetoxy Calcidiol (B3CD) in high-Risk Neuroblastoma. Chem Biol Drug Design. 2007;70:302-310.
18. Malich G, Markovic B, Winder C. The sensitivity and specificity of the MTS tetrazolium assay for detecting the in vitro cytotoxicity of 20 chemicals using human cell lines. Toxicology. 1997;124:179-192. (Pubitemid 28055528)
19. Hayakawa J, Ohmichi M, Kurachi H, et al. Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line. J Biol Chem. 1999;274:31648-31654. (Pubitemid 129501626)
20. Burrows CJ, Rokita SE. Recognition of guanine structure in nucleic acids by nickel complexes. Acc Chem Res. 1994;27:295-301.
21. Mandal SS, Varshney U, Bhattacharya S. Role of the central metal ion and ligand charge in the DNA binding and modification by metallosalen complexes. Bioconjugate Chem. 1997;8:798-812. (Pubitemid 27526407)
22. Routier S, Cotelle N, Catteau JP, et al. Salen-anthraquinone conjugates. Synthesis, DNA-binding and cleaving properties, effects on topoisomerases and cytotoxicity. Bioorg Med Chem. 1996;4:1185-1196. (Pubitemid 26284226)
23. Routier S, Bernier JL, Catteau JP, et al. Synthesis, DNA binding, and cleaving properties of an ellipticine-salen.copper conjugate. Bioconjugate Chem. 1997;8:789-792. (Pubitemid 27526405)
24. Woldemariam GA, Mandal SS. Iron(III)-salen damages DNA and induces apoptosis inhuman cells via mitochondrial pathway. J Inorg Biochem. 2008;102:740-747.
25. Routier, S Vezinh, Lamour E, Bernier JL, Catteau JP, Bailly C. DNA-cleavage by hydroxy-salicylidene-ethylendiamine-iron complexes. Nucl Acid Res. 1999;27:4160-4166.
26. Shapiro GI, Harper JW. Anticancer drug targets: cell-cycle and checkpoint control. J Clin Invest. 1999;104:1645-1653. (Pubitemid 30053178)
27. Gladden AB, Diehl JA. Cell-cycle progression without cyclin E/CDK2: breaking down the walls of dogma. Cancer Cell. 2003;4:160-162.
28. Mazumder S, DuPree EL, Almasan A. A dual role of cyclin E in cell proliferation and apoptosis may provide a target for cancer therapy. Curr Cancer Drug Targets. 2004;4:65-75. (Pubitemid 38332565)
29. Kim R, Emi M, Tanabe K, Murakami S, Uchida Y, Arihiro K. Regulation and interplay of apoptotic and non-apoptotic cell death. J Pathol. 2006;208:319-326. (Pubitemid 43210518)
30. Petit PX, Lecoeur H, Zorn E, Dauguet C, Mignotte B, Gougeon ML. Alterations in mitochondrial structure and function are early events of dexamethasone-induced thymocyte apoptosis. J Cell Biol. 1995;130:157-167.